LOS ANGELES, March 15, 2025 /PRNewswire/ -- CASEKOO recently hosted an enchanting "Tarot and Tea" soirée in Sai Wan, Hong Kong, to celebrate the grand launch of its collaborative collection, The Luminous Enigma series. This exquisite line of four phone cases, crafted in partnership with COCORRINA and renowned Tarot Reader Peter, draws inspiration from the celestial symbolism of the Sun and Moon tarot cards. The event welcomed passersby with open arms, offering each guest a comforting cup of spiced apple cinnamon tea upon entering the park. While many attendees were newcomers to the world of tarot, they were captivated by the intricate designs of the phone cases and the mystical allure of tarot itself. CASEKOO also unveiled the stories behind the collection, sharing the profound insights and intentions the designers imbued into each piece, hoping to inspire those who carry these cases to connect with their deeper meanings.
The Helios and Celene cases were born from the breathtaking beauty of Kefalonia, an island that holds deep personal significance for Corina, the visionary designer behind COCORRINA. Each morning, she finds herself nourished by the Sun's radiant energy, feeling a harmonious connection with the natural world. By night, she is guided by the Moon's gentle glow and the vast expanse of the sky, navigating life's ebbs and flows with grace. Through these meticulously crafted cases, Corina invites consumers to experience the celestial wonders that illuminate her daily life, offering a glimpse into her world with every creation.
Meanwhile, the Illuminating Sunlight and Midnight Moonlight designs were inspired by Tarot Reader Peter's profound connection to the Sun's boundless warmth and the Moon's quiet magic. The phrase "Let the sun shine heal you" encapsulates the Sun's restorative power, encouraging resilience and positivity in the face of life's challenges. Conversely, the Moon-inspired designs whisper "Embrace the Unknown," a gentle reminder to trust one's intuition, while "You look so beautiful tonight" celebrates the profound beauty found in darkness and the depths of emotion. Each piece in the collection pays homage to the enchanting interplay between the Sun's life-giving energy and the Moon's captivating mystique, offering a timeless connection to the cosmos and its profound duality.
Both designers, Corina and Peter, wish for more people to experience the breathtaking and awe-inspiring sights of the sun and moon that they cherish. They hope that whoever carries these cases will be enveloped in the sun's positive energy and drawn to the moon's enchanting gravity, finding inspiration and balance in their celestial harmony. Together, CASEKOO hopes that the owners of these cases will embrace the beauty of tarot, feeling their mysterious power and carrying it with them wherever they go.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
CASEKOO: Explore The Luminous Enigma and Let the enchanting artistry of Tarot Ignite your Intuition and Enlightenment.
TMB-365/TMB-380 Combination Demonstrates Viral Suspension Without the Need for Susceptibility Screening
TaiMed Biologics will reshape HIV treatment management and seeks strategic collaborations with global pharmaceutical partners for the commercialization of its long-acting HIV maintenance therapy
TAIPEI, March 18, 2025 /PRNewswire/ -- TaiMed Biologics (4147 TWO), an innovation-driven biotech company, has Phase 2a clinical study evaluating TMB-365/TMB-380 long-acting dual bNAb regimen for HIV maintenance therapy. This regimen, which is the first of its kind, offers a viable alternative to daily oral cART for individuals living with HIV.
Key findings from the trial include durable viral suppression, with 94% of participants maintaining RNA levels below 50 copies/mL throughout the treatment period, while only the remaining 6% of participants recorded viral load of 59 copies/mL at end of 24-week treatment. No pre-defined virologic failure, which were defined as two consecutive viral load measurements above 50 copies/mL.
The treatment was well-tolerated, with no serious adverse events, no Grade 3 or Grade 4, or acute infusion reactions reported. Additionally, no participants experienced treatment-limiting immune responses to the combination therapy.
One of the more remarkable findings of TMB-365/TMB-380 is that it does not require susceptibility screening as the combination's broad breadth of activity and high potency, participants were not pre-screened for susceptibility to either bNAb featured for lowering the barrier to treatment access and ensures a wider range of individuals living with HIV can benefit from the therapy.
Additionally, the pharmacokinetic (PK) and immunological markers also support the potential for long-acting viral suppression and stable immune function. This Phase 2a clinical trial was not a double-blind placebo-controlled study, and therefore, no statistical p-values were reported.
"We are honored that our study was accepted for late-breaking presentation at CROI, highlighting the high scientific merit and groundbreaking nature of our results among numerous research studies, TMB-365/TMB-380 is the first long-acting mAb combination to achieve a high rate of viral suppression without screening requirements with robust potency, broad coverage and low resistance risk The regimen aims to reduce the frequency of daily dosing, while maintaining treatment's efficacy," said Dr. Jimmy Chang, CEO of TaiMed Biologics.
"The global HIV treatment market valued at approximately USD 30 billion annually, with long-acting treatments currently account for only 3% but are projected to increase to over 30-40% in the coming years. The outstanding Phase 2a results position TMB-365/TMB-380 as a frontrunner in this rapidly growing sector, offering clear advantages over existing long-acting treatment options," emphasized by Dr. Jimmy Chang.
TaiMed Biologics is actively seeking strategic collaborations with global pharmaceutical partners to support the commercialization of TMB-365/TMB-380. TaiMed Biologics welcomes opportunities to explore potential collaborations with global pharmaceutical partners to advance the commercialization of TMB-365/TMB-380
For more information, please contact: Jonathan Ho, jho@taimedbio.com.
About TaiMed Biologics
Founded in 2007, TaiMed Biologics (4147.TWO) is a leading commercial-stage biotechnology company focused on developing innovative therapies for HIV treatment. The company successfully launched ibalizumab (Trogarzo®), the world's first and only FDA-approved monoclonal antibody for HIV and continues to pioneer long-acting biologics and antibody-drug conjugates (ADCs). TaiMed Biologics also offers comprehensive contract development and manufacturing (CDMO) services and is publicly traded on the OTC Market since November 2015, currently part of the MSCI Small Cap Index.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
TaiMed Biologics Announces Results from Late-Breaking Phase 2a Data on Long-Acting HIV Maintenance Therapy at CROI 2025
